COVID-19 Vaccine Supply Tracker Methodology

The “total secured courses” variable includes the following components:

1. Secured doses (excluding any optional doses on contracts) through bilateral agreements between countries and areas and vaccine manufacturers (excluding regional agreements which are handled separately below), collected through the COVAX Global Market Assessment by BMGF, CEPI, Gavi, PAHO Revolving Fund, UNICEF, and WHO largely leveraging public sources of information (e.g. press coverage).

2. Bilateral donations
   a. Data from UNICEF, national authorities, and other public sources

3. COVAX donations: vaccines through COVAX dose-sharing mechanism

4. Secured doses under the COVAX Facility
   a. COVAX Advanced Market Commitment (AMC): assuming 30% coverage for all AMC 91 economies and an estimated 150 million courses for India
   b. COVAX SFP: doses allocated to COVAX SFP-committed economies based on first several rounds of allocations

5. EU deal with manufacturers: member countries were allocated an amount proportional to their population

6. Other sources:
   a. Subset of the 220 million J&J doses that have been ordered through the African Vaccine Acquisition Trust (AVAT) (excludes the 180 million optional doses)
   b. Vaccines through COVAX cost-sharing mechanism
   c. Direct purchases financed by the World Bank that have already been executed and may not appear in the bilateral agreements yet

7. Domestic production capacity

8. Adjustments:
   a. Bilateral deals/bilateral donations/COVAX donations adjustments: based on secondary checks of the original numbers using various sources and dialogue with national authorities.
   b. Adjustments based on people vaccinated: when administered doses (based on WHO and Our World in Data reporting of the number of people who have been vaccinated) is greater than the sum of secured doses under deals, adjustments are made to reflect higher supply availability.

Note the term “secured doses” used here refers to doses countries and areas have committed to purchase under contracts with manufacturers. However, due to production schedules and issues as well as local
absorption capacity constraints, these doses may be made available to countries over varying time frames. We estimate that, based on current production schedules adjusted by production capacity estimates, countries and areas may need to wait well into 2022 or beyond to receive these secured doses.